Invesco Exchange-Traded Fund Trust Invesco Dorsey Wright Industrials Momentum ETF

PRN
$194.74 -1.71 (-0.87%)
Dividend Yield 0.28%
Payout Frequency Quarterly

Dividend History

Pay DateAmountEx-DateRecord Date
September 26, 2025$0.212025-09-222025-09-22
June 27, 2025$0.072025-06-232025-06-23
March 28, 2025$0.012025-03-242025-03-24
December 27, 2024$0.252024-12-232024-12-23
September 27, 2024$0.242024-09-232024-09-23

Dividends Summary

Company News

Should You Invest in the Invesco Dorsey Wright Industrials Momentum ETF (PRN)?
Zacks Investment Research • Zacks Equity Research • May 23, 2024

Sector ETF report for PRN

Profound Medical Annual General Meeting of Shareholders Voting Results
GlobeNewswire Inc. • Profound Medical Corp. • May 15, 2024

TORONTO, May 15, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX: PRN; NASDAQ: PROF) (“Profound” or the “Company”) is pleased to announce the voting results from its Annual General Meeting of Shareholders that was held today (the “Meeting”). A total of 15,336,388 common shares, representing 62.78% of the common shares outstandi...

5 Best-Performing Top-Ranked ETFs at the Start of May
Zacks Investment Research • Sweta Killa • May 10, 2024

Wall Street regained momentum at the start of May. The rally has been broad-based, with all three major indices just a few points away from their record highs.

Growing Body of Clinical Evidence Points to the Potential of Profound Medical’s TULSA Procedure Becoming a Mainstream Treatment Modality Across the Entire Prostate Disease Spectrum
GlobeNewswire Inc. • Profound Medical Corp. • May 6, 2024

— So far this year alone, 25 TULSA-related scientific research presentations have been delivered at major medical meetings around the world —

Profound Medical to Release First Quarter 2024 Financial Results on May 9 – Conference Call to Follow
GlobeNewswire Inc. • Profound Medical Corp. • April 22, 2024

TORONTO, April 22, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its first quarter 2024 financial results after market close ...

Related Companies